Key Highlights

• Processa Pharmaceuticals (NASDAQ:PCSA) appointed Gregory J. Flesher as Chief Operating Officer and three Executive Vice Presidents across research, development, and operations.

• The company is advancing VT-7208, a next-generation oral Bruton's tyrosine kinase inhibitor, in planned Phase 2 programs for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis.

• The FDA recently cleared an IND application for the planned Phase 2 study of VT-7208 in chronic spontaneous urticaria.

• The appointments follow Processa's July 2026 Acquisition of Vidya Therapeutics in a Reverse merger with approximately $200 million in concurrent financing.

Processa Pharmaceuticals Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company focused on immunological and inflammatory diseases, has named four senior executives to its Leadership team as it prepares for the next phase of development of its lead drug candidate, VT-7208.

Building a Team for Late-Stage Clinical Development

The newly appointed executives include Gregory J. Flesher as Chief Operating Officer, Craig Coburn, Ph.D., as Executive Vice President and Head of Research, Ashley Hall, J.D., as Executive Vice President of Development, and Michael P. Cruse as Executive Vice President of Business Operations. Flesher brings over 25 years of biopharmaceutical industry experience, having previously served as CEO at Ambros Therapeutics, Reneo Pharmaceuticals, and Novus Therapeutics. Coburn, who carries more than 30 years of medicinal chemistry experience, notably was one of the scientists who helped invent VT-7208 during his time as a scientific advisor to Vidya Therapeutics.

Hall, previously Chief Development Officer at Structure Therapeutics, has a track record in regulatory work including supporting programs for marketed drugs such as NEXLETOL, NEXLIZET, and REPATHA. Cruse served as COO at both Ambros Therapeutics and Reneo Pharmaceuticals.

The VT-7208 Pipeline Takes Shape

The leadership restructuring comes as Processa advances VT-7208, described as a next-generation, CNS-penetrant, once-daily oral Bruton's tyrosine kinase inhibitor. The company is planning Phase 2 proof-of-concept programs across three indications: food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis. The U.S. Food and Drug Administration has cleared an investigational new drug application for the CSU study, a development the company disclosed recently.

Additionally, Processa announced a research collaboration and exclusive option agreement with Generian Pharmaceuticals to advance a preclinical oral neonatal Fc receptor antagonist program, expanding the company's pipeline beyond BTK inhibition.

Foundation Set by the Vidya Therapeutics Merger

These leadership moves build on the foundation laid by Processa's July 2026 acquisition of Vidya Therapeutics in a sign-and-close reverse merger, which was accompanied by a concurrent private Placement financing of approximately $200 million. That transaction established the company's current clinical and pipeline strategy, with VT-7208 becoming the lead program. The merger effectively repositioned Processa from its prior pipeline focus into an I&I-focused clinical-stage company with a differentiated asset and Capital to pursue multiple proof-of-concept studies.

Sheila Gujrathi, M.D., Executive Chair of the Processa Board, highlighted the complementary nature of the new hires, noting the team's collective experience across research, development, and operations.

What It All Means

The four senior appointments mark a deliberate effort by Processa Pharmaceuticals to assemble the operational infrastructure needed to carry VT-7208 through late-stage clinical trials. With FDA clearance for the CSU study in hand, a well-funded Balance Sheet following the Vidya merger, and a diversifying pipeline, the company is positioning itself for a series of clinical catalysts in 2027. The pace of execution in the coming quarters will determine whether these organizational moves translate into meaningful clinical progress.